EXCHANGE STUDENTS Sample Clauses

EXCHANGE STUDENTS. All exchange students are required to pay the following fees:
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
EXCHANGE STUDENTS. Consistent with current Policy JFABB “Foreign Exchange Students,” exchange students from the sending district have the opportunity to be placed in the AREA schools without additional charge to the sending district, as long as the total number of exchange students allowed by receiving district policies, and as may be amended, is not exceeded. Both districts shall have equal access to exchange student positions. In the event that the receiving district should waive this policy and accept additional exchange students from the sending district, the student's tuition expense shall be paid by the sending district at the full rate of tuition for that school. The sending district shall be notified and pre-approve this waiver.
Sample 1Sample 2
EXCHANGE STUDENTS. A. The anticipated enrollment pursuant to this Agreement is ( ) Exchange Students per institution, per academic term.
Sample 1
EXCHANGE STUDENTS. In general, we are not able to guarantee Accommodation to students on an exchange programme. There are some exceptions to this which are agreed by the University of Southampton with our partner institutions. Please contact Residences on xxxxxxxxxxxxx@xxxxx.xx.xx. Cars – Student Car Restriction Arrangement
Sample 1
EXCHANGE STUDENTS. A. The anticipated enrollment pursuant to this Agreement is six (6) Exchange Students per institution, per academic term.
Sample 1
EXCHANGE STUDENTS. Some will use the contract registration process, while others will register with a CRN. Check with the International Programs office regarding your specific exchange program.
Sample 1
EXCHANGE STUDENTS. An exchange student is registered at a university (home university) and temporarily studies at a partner university (i.e. Host University). Exchange students do not have to obtain a qualification from the host institution. However, all academic results will be sent to the students' home university and will be recognized using the two ECTS (European Credit Transfer System) tools: the learning agreement and the transcript of records. The Partners commit to using the ECTS system or to convert the local grades and credits into the ECTS system in order to facilitate the academic recognition for each participating student. Exchange students need the approval of their home and host university. The Partners commit to recognizing the mobility period abroad based on a Learning Agreement that will be signed by the home university and the host university. Exchange students pay registration or tuition fees to the respective home university (where applicable) and must not pay registration or tuition fees at the host university.
Sample 1
AutoNDA by SimpleDocs

Related to EXCHANGE STUDENTS

  • MEDICALLY FRAGILE STUDENTS 1. If a teacher will be providing instructional or other services to a medically fragile student, the teacher or another adult who will be present when the instruction or other services are being provided will be advised of the steps to be taken in the event an emergency arises relating to the student's medical condition.

  • Transporting Students Teachers shall not be required to transport a student in a private vehicle on behalf of the school.

  • Students Payments which a student or business apprentice who is or was immediately before visiting a Contracting State a resident of the other Contracting State and who is present in the first-mentioned State solely for the purpose of his education or training receives for the purpose of his maintenance, education or training shall not be taxed in that State, provided that such payments arise from sources outside that State.

  • Academic Program A. Upon successful completion of the major requirements, as indicated below, SDSU will accept 48 technical course credits from the A.A.S. degree in Library Technician. Additional transferable system general education credits may be earned at WDT and may be transferred to SDSU. Students must meet all Board of Regents policies and university graduation requirements in order to receive a degree.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Medicaid Program Parties (applicable to any Party providing services and supports paid for under Vermont’s Medicaid program and Vermont’s Global Commitment to Health Waiver):

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Cooperation with Economic Studies If ICANN initiates or commissions an economic study on the impact or functioning of new generic top-­‐level domains on the Internet, the DNS or related matters, Registry Operator shall reasonably cooperate with such study, including by delivering to ICANN or its designee conducting such study all data related to the operation of the TLD reasonably necessary for the purposes of such study requested by ICANN or its designee, provided, that Registry Operator may withhold (a) any internal analyses or evaluations prepared by Registry Operator with respect to such data and (b) any data to the extent that the delivery of such data would be in violation of applicable law. Any data delivered to ICANN or its designee pursuant to this Section 2.15 that is appropriately marked as confidential (as required by Section 7.15) shall be treated as Confidential Information of Registry Operator in accordance with Section 7.15, provided that, if ICANN aggregates and makes anonymous such data, ICANN or its designee may disclose such data to any third party. Following completion of an economic study for which Registry Operator has provided data, ICANN will destroy all data provided by Registry Operator that has not been aggregated and made anonymous.

Time is Money Join Law Insider Premium to draft better contracts faster.